The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

It’s become a familiar tragedy: someone is prescribed pain medication to recover from an injury, then becomes addicted to the medication intended to improve their life. It’s left both healthcare professionals and people recovering from surgery in a difficult position: should you take medication that will make your life more manageable if there’s a risk

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare providers address pain management. Suzetrigine, also known as Journavx, is classified within a new category of pain management medication without the same addictive qualities seen in many of its opiate competitors.